Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of intravenous otamixaban versus unfractionated heparin in non-urgent PCI
2004-000904-41Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2004
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis comparing Otamixaban dose-ranging arms with Unfractionated heparin control arm (2 arms). Primary endpoint: Primary pharmacodynamic markers. Started Aug 2004; status: completed.
02
Drugs
otamixabanheparin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2004-000904-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000904-41.